GGiantBullStocks

Summit Therapeutics Inc. (SMMT)

NASDAQ · Healthcare

$13.50-2.24%

As of Jul 20, 2026

Price history

Key statistics

Market cap
$11.84B
P/E ratio
EPS
Volume
2,704,270
52-week high
52-week low
Open
$13.74
Day high
$14.35
Day low
$13.49

Financial highlights

Fiscal yearRevenueNet incomeEPS
2025-$1.08B-$1.44
2024$0-$221.32M-$0.31
2023$0-$614.93M-$0.99
2022$705K-$78.78M-$0.41
2021$1.81M-$88.6M-$0.67

About Summit Therapeutics Inc.

Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing therapeutic solutions, primarily targeting infectious diseases across the United States and Latin America. The company's clinical development pipeline is heavily concentrated on therapies for Clostridioides difficile infection (CDI). Its flagship product candidate, ridinilazole, is an orally administered small molecule antibiotic currently advancing through Phase III clinical trials as a treatment for CDI. Beyond its lead asset, Summit Therapeutics is also progressing SMT-738, designed to combat multidrug-resistant infections, notably carbapenem-resistant Enterobacteriaceae (CRE). Additionally, its DDS-04 series represents a potential therapeutic avenue for various infections caused by the Enterobacteriaceae family of bacteria. Established in 2003, the company maintains its headquarters in Cambridge, Massachusetts.

CEO
Robert W. Duggan
Employees
265
Country
US
IPO date
Mar 5, 2015

Similar stocks

Other Healthcare companies

Frequently asked questions

What is Summit Therapeutics Inc.'s stock price today?
SMMT is trading at $13.50 as of Jul 20, 2026.
What is Summit Therapeutics Inc.'s market cap?
Summit Therapeutics Inc. (SMMT) has a market capitalization of $11.84B.
Does Summit Therapeutics Inc. pay a dividend?
Summit Therapeutics Inc. did not pay a dividend in its most recent reported fiscal year.
What sector is Summit Therapeutics Inc. in?
Summit Therapeutics Inc. operates in the Healthcare sector.